Avant Genomics Secures $3M+ in Funding to Accelerate First-in-kind Automated Platform for Liquid Biopsy Sample Preparation
Avant Genomics™, a pioneer in fully-automated liquid biopsy sample preparation for precision cancer detection, today announced the successful raise of more than $3 million to advance development of its automated platform for liquid biopsy sample preparation. TitletownTech, Halyard Ventures, Virginia Venture Partners, CAV Angels, Global Impact Fund, and additional angel investors and family offices participated in the round. The new capital will support continued R&D, accelerate manufacturing, and expand the team’s expertise with additional hires.
